Translating cancer biology research into novel oncology treatments

Successful in Funding Application

Today (Friday 21 February 2014) Cancer Therapeutics CRC received the decision from the CRC Program that the application for six years extension funding was approved. Read media release...

Drug Discovery Targets

Cancer Therapeutics CRC is a small molecule drug discovery company that is translating innovative cancer biology research into lead and preclinical stage drug candidates. In particular it is targeting novel cancer pathways associated with the tumour microenvironment or growth, to develop novel treatments for breast, prostate, melanoma, lung and brain cancers. Read more...

Partnering

Cancer Therapeutics CRC has a pipeline of innovative early stage small molecule oncology programs, backed up with data-rich packages, which are available for partnering or out-licensing. Read more...

 
© Cancer Therapeutics CRC 2014   Website by College Hill